BCM
GNMK

BlueCrest Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

BlueCrest Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,693
Closed -$126K – 1166
2017
Q2 		$126K Buy
+10,693
New +$137K ﹤0.01% 802

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlueCrest Capital Management's GNMK Position: Q3 2017 in Review

BlueCrest Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2017, closing a stake of 10,693 shares — an estimated $126K sold.

BlueCrest Capital Management first reported a position in GNMK in Q2 2017 and held it in 1 quarter. The position peaked at $126K in Q2 2017. 96 funds tracked by Wall St. Rank hold GNMK as of Q3 2017.

  • BlueCrest Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,693 GenMark Diagnostics, Inc shares in Q3 2017, an estimated $126K.
  • BlueCrest Capital Management first reported a position in GenMark Diagnostics, Inc in Q2 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's GenMark Diagnostics, Inc position peaked at $126K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2017.

Based on BlueCrest Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.